Please use this identifier to cite or link to this item:
|Title:||Investigation burden for patients with fibrotic interstitial lung disease at the end of life.|
|Authors:||Guo, Hui;Mann, Jennifer;Goh, Nicole S L;Smallwood, Natasha|
|Affiliation:||Department of Medicine (Royal Melbourne Hospital), University of Melbourne, Melbourne, Victoria, Australia|
Department of Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia
Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia
|Citation:||Internal Medicine Journal 2020; 50(6): 748-752|
|Abstract:||Fibrotic interstitial lung disease (f-ILD) has a guarded prognosis, and the goal of therapy in advanced-stage disease should be symptom-based. Despite this, patients may still undergo burdensome investigation at the end of life. A retrospective audit was performed on 67 patients who died from f-ILD at the Royal Melbourne and Austin Hospitals between 2012 and 2016. Increased investigation burden was associated with lack of outpatient palliative care referral and documented advance care plan, and admission to a high-dependency unit. Eighteen per cent of patients underwent ongoing investigations after the institution of comfort care. These findings highlight the unmet end-of-life care needs of people with f-ILD.|
interstitial lung disease
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.